share_log

Gilead Sciences | 10-Q: Q3 2024 Earnings Report

Gilead Sciences | 10-Q: Q3 2024 Earnings Report

吉利德科学 | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/12 08:32

Moomoo AI 已提取核心信息

Gilead Sciences reported Q3 2024 revenues of $7.5 billion, up 7% year-over-year, driven by strong HIV product sales which increased 9% to $5.1 billion. Net income was $1.3 billion, with diluted EPS of $1.00, compared to $2.2 billion and $1.73 in Q3 2023. The decline was primarily due to a $1.8 billion impairment charge related to Trodelvy's NSCLC program.Product performance was led by Biktarvy with sales up 13% to $3.5 billion on higher demand and pricing. Trodelvy sales grew 17% to $332 million, while Veklury (remdesivir) sales increased 9% to $692 million due to higher COVID-19 hospitalizations. Cell therapy revenues remained flat at $485 million as Yescarta faced increased competition.The company announced plans to voluntarily withdraw Trodelvy's U.S. accelerated approval in urothelial cancer following unsuccessful confirmatory trial results. Management highlighted continued execution of strategic priorities, including the completion of CymaBay acquisition for $3.9 billion and FDA approval of Livdelzi for primary biliary cholangitis.
Gilead Sciences reported Q3 2024 revenues of $7.5 billion, up 7% year-over-year, driven by strong HIV product sales which increased 9% to $5.1 billion. Net income was $1.3 billion, with diluted EPS of $1.00, compared to $2.2 billion and $1.73 in Q3 2023. The decline was primarily due to a $1.8 billion impairment charge related to Trodelvy's NSCLC program.Product performance was led by Biktarvy with sales up 13% to $3.5 billion on higher demand and pricing. Trodelvy sales grew 17% to $332 million, while Veklury (remdesivir) sales increased 9% to $692 million due to higher COVID-19 hospitalizations. Cell therapy revenues remained flat at $485 million as Yescarta faced increased competition.The company announced plans to voluntarily withdraw Trodelvy's U.S. accelerated approval in urothelial cancer following unsuccessful confirmatory trial results. Management highlighted continued execution of strategic priorities, including the completion of CymaBay acquisition for $3.9 billion and FDA approval of Livdelzi for primary biliary cholangitis.
吉利德科学报告2024年第三季度收入为75亿，较上年增长7%，主要受强劲的HIV产品销售推动，销售额增加了9%，达到51亿。净利润为13亿，摊薄后每股收益为1.00美元，而2023年第三季度为22亿和1.73美元。下降主要是由于与Trodelvy的NSCLC项目相关的18亿减值费用。产品表现由Biktarvy主导，销售额增加了13%，达到35亿，主要得益于需求和价格的上升。Trodelvy销售额增长了17%，达到33200万，而Veklury（瑞德西韦）销售额也因新冠病毒住院患者增加而上涨了9%，达到69200万。电芯疗法收入保持在48500万，因为Yescarta面临着竞争加剧的问题。该公司宣布计划自愿撤回Trodelvy在泌尿上皮癌的美国加速审批，因为确认性试验结果不成功。管理层强调了战略优先事项的持续执行，包括以39亿完成CymaBay的收购和FDA批准Livdelzi用于原发性胆汁性胆管炎。
吉利德科学报告2024年第三季度收入为75亿，较上年增长7%，主要受强劲的HIV产品销售推动，销售额增加了9%，达到51亿。净利润为13亿，摊薄后每股收益为1.00美元，而2023年第三季度为22亿和1.73美元。下降主要是由于与Trodelvy的NSCLC项目相关的18亿减值费用。产品表现由Biktarvy主导，销售额增加了13%，达到35亿，主要得益于需求和价格的上升。Trodelvy销售额增长了17%，达到33200万，而Veklury（瑞德西韦）销售额也因新冠病毒住院患者增加而上涨了9%，达到69200万。电芯疗法收入保持在48500万，因为Yescarta面临着竞争加剧的问题。该公司宣布计划自愿撤回Trodelvy在泌尿上皮癌的美国加速审批，因为确认性试验结果不成功。管理层强调了战略优先事项的持续执行，包括以39亿完成CymaBay的收购和FDA批准Livdelzi用于原发性胆汁性胆管炎。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Medicus Pharma
    MDCX
    -- 3.680
    Scilex Holding
    SCLX
    -- 0.354
    阿玛琳
    AMRN
    -- 0.612
    赛诺菲安万特
    SNY
    -- 54.500
    艾伯维公司
    ABBV
    -- 192.870
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    特斯拉绩后巨震，后市你怎么看？
    特斯拉2024年Q4营收257.1亿美元，同比增长2%，不及预期。Cybercab计划2026年投产，预计车辆业务将于2025年恢复增长。面对特朗普回归，特斯拉股价能否在2025年继续攀升？ 展开
    TSLA财报预告：通过猜测开盘价来获取奖励！